ProCE Banner Activity

Reversing DOAC-Associated Major Bleeding—Follow the Data

Clinical Thought
What do the data tell us about DOAC reversal as a strategy for controlling major bleeding? Have we been using agents in strategies unsupported by data?

Released: January 05, 2022

Expiration: January 04, 2023

No longer available for credit.



Charles “Kurt” Mahan

Charles “Kurt” Mahan, PharmD, PhC, FASHP, FCCP

Provided by

Provided by ProCE, LLC
ProCE Banner


This activity is supported by an educational grant from


AstraZeneca Rare Disease

Faculty Disclosure

Primary Author

Charles “Kurt” Mahan, PharmD, PhC, FASHP, FCCP

Charles “Kurt” Mahan, PharmD, PhC, FASHP, FCCP, has disclosed that he has received funds for research support from Alexion, AstraZeneca, and Portola; consulting fees from Alexion, AstraZeneca, Janssen, and Portola; and fees for non-CME/CE services from Alexion, AstraZeneca, Bristol-Myers Squibb, Janssen, Pfizer, and Portola.